SRDAN VERSTOVSEK to Enzyme Inhibitors
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Enzyme Inhibitors.
Connection Strength
1.116
-
Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival. Oncology (Williston Park). 2013 Jul; 27(7):717-8.
Score: 0.258
-
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer. 2012 Feb 15; 118(4):870-7.
Score: 0.226
-
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticancer Ther. 2009 May; 9(5):663-70.
Score: 0.194
-
JAK2 inhibitors: A reality? A hope? Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S340-5.
Score: 0.189
-
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96.
Score: 0.044
-
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404.
Score: 0.042
-
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56.
Score: 0.037
-
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83.
Score: 0.033
-
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34.
Score: 0.032
-
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8.
Score: 0.032
-
Advances in the management of myelofibrosis. Cancer Control. 2012 Oct; 19(4 Suppl):4-15.
Score: 0.015
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
Score: 0.013